Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Published:2010-08 Issue:4 Volume:10 Page:262-269
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Lignon Julie,Sibon David,Madelaine Isabelle,Brice Pauline,Franchi Patricia,Briere Josette,Mounier Nicolas,Gisselbrecht Christian,Faure Pierre,Thieblemont Catherine

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference26 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

3. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP);Velasquez;Blood,1988

4. EPIC: an effective low toxicity regimen for relapsing lymphoma;Hickish;Br J Cancer,1993

5. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients;Aydin;Ann Hematol,2007

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma;Blood Reviews;2024-01

2. Construction and Validation of a Novel Nomogram for Predicting the Recurrence of Diffuse Large B Cell Lymphoma Treated with R-CHOP;Pharmacogenomics and Personalized Medicine;2023-04

3. Cisplatin in cancer treatment;Biochemical Pharmacology;2022-12

4. All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma;Frontiers in Oncology;2022-05-10

5. Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group;Cancers;2022-03-30